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Osteosarcoma is the most common primary malignancy of bone. Most cases are sporadic without a known genetic or
environmental cause. Heritable genetic predisposition syndromes are associated with a small percentage of osteosarcomas. Study
of these rare disorders has provided insight into the molecular pathogenesis of osteosarcoma. Screening of at-risk families and
surveillance of affected individuals for these syndromes may permit earlier diagnosis and more effective treatment of osteosarcoma
in these populations. This paper reviews the genetic and clinical features of the known osteosarcoma predisposition syndromes.
1. Introduction
Osteosarcoma is the most common primary malignant bone
tumor. It has a bimodal age distribution with the larger peak
among adolescents and young adults and a second small-
er peak among the elderly [1]. The majority of osteosarcoma
cases are sporadic with no identifiable genetic or environ-
mental cause [2]. A small and unknown percentage of osteo-
sarcomas occur in individuals with cancer predisposition
syndromes. A review of the Dutch National Pathology Regis-
ter identified secondary malignancies in 7% of osteosarcoma
patients, indicating possible hereditary cancer syndromes in
these patients [3]. A nationwide study from Sweden found
significant associations between childhood osteosarcoma
and several parental cancers including rectal cancer, colon
cancer, endocrine cancers, melanoma, and breast cancer [4].
The known osteosarcoma predisposition syndromes
include Li-Fraumeni syndrome (LFS), hereditary retinoblas-
toma (RB), Rothmund-Thomson syndrome (RTS) type 2,
Werner syndrome (WS), Bloom syndrome (BS), RAPADIL-
INO syndrome, and Diamond Blackfan anemia (DBA).
The epidemiology, clinical findings, genetics, treatment, and
screening recommendations for these syndromes will be re-
viewed. Additionally, insights into the pathogenesis of oste-
osarcoma derived from these syndromes will be discussed.
2. Li-Fraumeni Syndrome (TP53)
2.1. Description and Diagnosis. In 1969, Li and Fraumeni
described a clinical phenotype and syndrome associated with
soft tissue sarcomas, breast cancer, and other cancers [5].
Germline mutations of the TP53 gene were first identified
among familial cohorts with LFS in 1990 (Table 1) [6, 7].
TP53 acts as a cell cycle regulator, and mutations of TP53
are found in approximately 50% of human cancers [8]. This
mutation has subsequently been identified as causative in
approximately 70% of individuals with LFS [9, 10]. Another
gene, CHEK2, was initially believed to be the responsible
gene in some of the LFS families who did not have TP53
mutations. Subsequent research suggests that this association
is unlikely [11, 12]. LFS is inherited as an autosomal
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Table 1: Osteosarcoma predisposition syndromes and their associated genes.
Syndrome Inheritance Genes Gene product Chromosome
Li-Fraumeni AD TP53 Tumor suppressor 17p13.1
Retinoblastoma AD RB1 Tumor suppressor 13q14.2
Rothmund Thomson II AR REQ4 DNA helicase 8q24.3
RAPADILINO AR REQ4 DNA helicase 8q24.3
Werner AR WRN DNA helicase 8p12
Bloom AR BLM DNA helicase 15q26.1
Diamond Blackfan AD
RPS19, RPL5, RPL11, RPL35A,
RPS24, RPS17, RPS7, RPS10, RPS26
Ribosomal
Protein
Multiple
Table 2: Li-Fraumeni diagnosis and screening criteria.
Classic Li-Fraumeni Criteria
Proband diagnosed with a sarcoma before age 45
First-degree relative with any cancer before age 45
First- or second-degree relative with any cancer before age 45 or a sarcoma at any age
Li-Fraumeni-like Criteria
Proband with any childhood cancer, sarcoma, brain tumor, or adrenocortical carcinoma before age 45
First- or second degree relative with sarcoma, brain tumor, adrenocortical carcinoma, or leukemia at any age
First- or second-degree relative with any cancer before age 60
2009 Chompret Criteria for TP53 testing
(I) Proband with tumor belonging to LFS tumor spectrum (e.g., soft tissue sarcoma, osteosarcoma, brain tumor, premenopausal breast
cancer, adrenocortical carcinoma, leukemia, and lung bronchoalveolar cancer) before age 46 years and at least one first- or second-degree
relative with LFS tumor (except breast cancer if proband has breast cancer) before age 56 years or with multiple tumors; or
(II) Proband with multiple tumors (except multiple breast tumors), two of which belong to LFS tumor spectrum and first of which occurred
before age 46 years; or
(III) Patient with adrenocortical carcinoma or choroid plexus tumor, irrespective of family history
dominant disease and has been identified among cohorts
throughout the world. Diagnosis of LFS is based upon
clinical criteria as not all families with a classic presentation
carry the TP53 mutation. In addition to families with “classic
LFS,” there are also numerous reported families who have
abnormally high rates of cancers and increased rates of
TP53 mutations. These cohorts have been diagnosed with
Li-Fraumeni-like (LFL) syndrome. Published criteria for LFS
and LFL syndrome are listed in Table 2 [13, 14].
Sarcomas, premenopausal breast cancer, brain tumors,
and adrenocortical carcinomas account for the majority of
cancers among LFS and LFL patients and are considered
the “classic” Li-Fraumeni cancers. However, almost every
type of known cancer is overrepresented in this population
including lung cancer, leukemia, lymphoma, stomach cancer,
colon and rectal cancer, ovarian cancer, and melanoma [15].
Osteosarcoma is themost prevalent bone sarcoma in LFS, but
chondrosarcomas have also been reported. In a review of 24
families, 18 of 151 affected individuals developed osteosar-
coma. There were three chondrosarcomas in the same study
[13]. Ewing sarcoma has not been associated with LFS or
any other hereditary cancer syndrome [15]. The presentation
of osteosarcoma among LFS patients is similar to sporadic
osteosarcoma with respect to location. Age at presentation of
LFS-associated osteosarcomas is younger than in the general
population [16]. Some authors have suggested that genetic
anticipation and progressive shortening of telomere length
is at least partially responsible for this finding [17]. Although
LFS and germline TP53 mutations are rare in the population,
the TP53 gene is frequently mutated in tumor samples from
a variety of cancers in non-LFS patients including osteosar-
coma. Somatic TP53 mutations are identified in 15–30% of
all osteosarcoma specimens with the variation depending on
the testing methods and study population used [18, 19].
2.2. Treatment and Screening for LFS. Cancers which occur in
individuals with LFS are generally treated with standard ther-
apy for the specific cancer in question. The major exception
to this principle is that radiation exposure for LFS patients
should be minimized if possible [20]. For example, mastec-
tomy is often recommended for breast cancer in LFS patients
in order to avoid the need for adjuvant radiotherapy. A recent
report from France reviewed eight LFS patients with breast
cancer as their first diagnosis. Three of the eight received con-
servative breast surgery and radiation instead of mastectomy,
and an additional three patients received radiation therapy
in addition to mastectomy. All three lumpectomy patients
developed recurrent local disease. Additionally, there were
two radiation-induced sarcomas among the six patients who
received radiation [21]. Radiotherapy does not play as large
of a role in the treatment of osteosarcoma. However, chest
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Table 3: NCCN Li-Fraumeni screening guidelines.
Breast self-exam training and education starting at age 18 years
Clinical breast exam, every 6–12 months, starting at age 20–25 years or 5–10 years before the earliest known breast cancer in the family
(whichever comes first).
Annual mammogram or breast MRI starting at age 20–25 years or individualized based upon the earliest age of onset in the family.
Annual comprehensive physical exam; include careful skin and neurologic examinations
Consider colonoscopy every 2–5 years starting no later than age 25 years.
Targeted surveillance based on individual family histories
Discuss options to participate in novel screening approaches using technologies such as PET, abdominal ultrasound, and brain MRI within
clinical trials when possible.
Recommend genetic counseling and consideration of genetic testing for at-risk relatives.
computed tomography (CT) and bone scans are routinely
used for preoperative staging and posttreatment surveillance
of osteosarcoma patients. Current surveillance guidelines
require as many as 15 posttreatment chest imaging studies
(NCCN, Bone Cancer, Version 2, 2011). Use of chest radio-
graphs instead of CT scans decreases radiation exposure in
the LFS population. Whole body magnetic resonance imag-
ing (MRI) has been proposed as a screening and surveillance
imaging alternative which completely avoids the use of radi-
ation in this population [22]. In fact, a recent study showed
that annual whole body MRI combined with blood tests for
common LFS cancers can facilitate early detection of cancers
and decrease mortality of LFS patients [23]. The National
Comprehensive Cancer Network (NCCN) guidelines for
cancer screening among LFS patients are listed in Table 3.
Other NCCNmanagement recommendations include avoid-
ance of radiation therapy if possible and consideration of
prophylactic mastectomies in some high-risk patients.
Genetic counseling and testing should be offered to
individuals at high risk of having germline TP53 mutations.
These include family members of individuals known to have
germline TP53 mutations or who meet classic LFS criteria.
Additionally, Chompret et al. developed TP53 testing criteria
[24] to identify mutations among individuals and families
not meeting classic LFS criteria (Table 2). These criteria
were recently updated to include testing of any individual,
regardless of age, with a history of adrenocortical carcinoma
or choroid plexus carcinoma [25]. Another recent study fur-
ther validated the 2009 Chompret criteria and additionally
supported the testing of breast cancer patients under the age
of 30 years if BRCA1/BRCA2 mutations are not identified
[26]. Some geneticists will also test for TP53 mutations in
osteosarcoma patients presenting before 10 years of age.
3. Hereditary Retinoblastoma
3.1. Description and Diagnosis. Hereditary retinoblastoma is
a rare, autosomal dominant disease which causes malignant
eye tumors in children and an increased risk of subsequent
malignancies, especially osteosarcomas, later in life. Retino-
blastomas, the primary tumors involved in the disease, arise
from developing retinal tissue in young children. The retino-
blastoma cell of origin has not been fully defined [27].
Although rare, retinoblastoma is the most common intraoc-
ular cancer with an incidence of 1 in 16,000 to 1 in 18,000 live
births [28]. Retinoblastoma affects all races and geographic
regions. Retinoblastoma is one of themost treatable pediatric
cancers with 5-year actuarial survival rates in the USA over
95% between 1995 and 2004 [29]. The diagnosis of retino-
blastoma is based upon clinical eye exams. Young, at-risk pa-
tients may require exam under anesthesia to confirm the dia-
gnosis. Modern treatment for retinoblastoma, even for the
heritable form, is often less morbid than in the past as enucle-
ation of the eye often can be avoided with the use of chemo-
therapy [30].
Heritable retinoblastoma is caused by a mutation of the
RB1 tumor suppressor gene. The study of heritable retino-
blastoma has provided fundamental insights into cancer
biology. In 1971, Albert Knudson proposed the “two-hit
hypothesis” of cancer development based upon statistical
analysis of hereditary and spontaneous retinoblastoma cases
[31]. Fundamentally, the hypothesis states that cancer results
from accumulated mutations, a “first hit” followed by a “sec-
ond hit.” In retinoblastoma, cancer develops when a second
spontaneous RB1 mutation occurs in addition to the ger-
mlinemutation. The hypothesis was confirmed in 1986 when
RB1 became the first cancer susceptibility gene identified
in humans [32]. Approximately 42% of retinoblastoma
cases were heritable in a large cohort from the United King-
dom [33]. The RB1 gene product functions as a cell cycle
regulator. Homozygous deficiency of RB1 is lethal [34].
Similar to TP53, somatic mutations of RB1 are frequently
found in tumor specimens from sporadic cases of osteosar-
coma and many other cancers. Somatic mutations of RB1
are found in 30–75% of osteosarcoma specimens depending
on the testing techniques utilized and the population studied
[35]. Nearly all osteosarcomas are felt to have the RB1 path-
way disrupted, some tumors accomplishing this with
p16/INK4A silencing or CDK4/Cyclin D1 overexpression
[36–38]. In addition to osteosarcoma, hereditary retinoblas-
toma predisposes individuals to soft tissue sarcomas (espe-
cially leiomyosarcoma), melanoma, and brain tumors. There
is also a small increase in overall carcinoma rates (especially
lung, breast, and bladder) compared to background rates of
the general population [39–41]. We continue to learn about
more cancers in patients with inherited retinoblastoma as
this population now ages.
Osteosarcoma is the most common secondary malig-
nancy in patients with hereditary retinoblastoma. Determin-
ing the epidemiology and natural history of osteosarcoma
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in patients with retinoblastoma was initially complicated by
the widespread use of radiation therapy for primary retino-
blastoma treatment. A 1997 study of 1,604 retinoblastoma
patients diagnosed between 1914 and 1984 revealed a 400-
fold increased risk of osteosarcoma among hereditary retino-
blastoma patients [40]. Much of this increased risk resulted
from the combination of genetic susceptibility and the use of
radiation therapy. The same authors noted that both bone
and soft tissue sarcoma rates were increased by radiation
exposure in a dose-dependent fashion. Moreover, 69% of the
osteosarcomas in the study occurred in the head. Fletcher
et al. reported a British hereditary retinoblastoma cohort of
patient born between 1873 and 1950 when external beam
radiation was infrequently used for retinoblastoma [42].
Only 8 of 144 (5.5%) patients developed sarcomas of any
type, while the overall incidence of secondary malignancy
remained high. Another study from the United Kingdom
identified a 200-fold increased rate of osteosarcoma among
809 heritable retinoblastoma patients diagnosed between
1951 and 2004 [43]. The same study also concluded that
the osteosarcomas generally occurred in adolescents and
young adults, similar to sporadic cases. Radiation use, radia-
tion dosage, and osteosarcoma site were not reported in
this study. However, it is important to remember that even
patients with hereditary retinoblastoma who did not receive
radiation exposure are still at increased risk for the develo-
pment of osteosarcoma due to their underlying RBmutation.
3.2. Treatment and Screening. Treatment of primary disease
among hereditary retinoblastoma patients has evolved over
the past several decades. External beam radiation is used
less frequently and in lower doses. Enucleation rates are
lower and vision is preserved more frequently than in the
past [44]. Retinoblastoma patients with osteosarcoma are
treated with standard chemotherapy protocols. One 2003
study from Spain suggested that osteosarcoma patients with
loss of heterozygosity of RB1 had worse prognosis [45]. This
has not been confirmed among other cohorts. Similar to LFS
patients, ionizing radiation exposure of retinoblastoma pa-
tients should be limited if possible due to the risk of radia-
tion-induced sarcomas. Unlike LFS, there are no established
surveillance guidelines for secondary malignancies among
retinoblastoma survivors [46]. Patient and family education
should emphasize avoidance of environmental carcinogens
such UV radiation, ionizing radiation, and tobacco use.
Heightened concern for lingering musculoskeletal symptoms
or unexplained masses is prudent due to the increased inci-
dence of sarcomas. Increased breast health vigilance (self-
exam, clinical exam, and mammography) has also been ad-
vocated by some authors due the limited but observed in-
crease in breast cancer among retinoblastoma patients [47,
48].
Genetic testing for RB1 mutations is routinely offered
to affected individuals and their families. Testing is valuable
for distinguishing sporadic from familial cases. The Ameri-
can Society of Clinical Oncology recommends that genetic
testing should be part of the standard treatment for indi-
viduals and first-degree relatives with retinoblastoma cancer
predisposition disorder [49]. Genetic testing is strongly rec-
ommended because intensive surveillance of newborns with
the mutation can lead to early detection and more effective,
vision sparing treatment. Overall survival is increased and
enucleation rates are decreased with early detection [50].
Intensive screening requires eye examinations every 3 to 4
weeks until age three. This regimen often requires repeated
examinations under anesthesia. This regimen can be avoided
in unaffected familymembers identified with the use of gene-
tic testing. The possibility of somatic and germline mosaici-
sm must also be considered when recommending genetic
testing and interpreting its results. A small percentage (ap-
proximately 5%) of unilateral retinoblastoma patients with
no family history of the disease develop contralateral retino-
blastomas despite having negative blood leukocyte tests for
RB1 mutations [51]. Some individuals with themutation will
have a less than a fifty percent chance of transmitting the
disease due to germline mosaicism. The added complexity of
mosaicism emphasizes the importance of referral to genetic
counseling in addition to testing.
4. RecQ Disorders Associated with
Osteosarcoma Predisposition
4.1. Introduction. DNA helicases are proteins which aid in
the unwinding of double-stranded DNA during replication
and repair. There are several different helicases, and the
function ofmany is not yet fully elucidated. Four very rare sy-
ndromes associated with osteosarcoma predisposition are
caused by mutations of the RecQ family of helicase genes.
There are five known members of the RecQ family in hu-
mans, three of which have been associated with syndromes
[52]. Unlike LFS and retinoblastoma, the helicase syndromes
are autosomal recessive and have distinct physical findings.
Table 4 lists the most common phenotypic findings of the
RecQ osteosarcoma predisposition syndromes. Of the four
RecQ syndromes, Rothmund-Thomson Syndrome is most
strongly associated with osteosarcoma predisposition. Over-
lapping findings of the four syndromes include chromosomal
instability, growth retardation, dermatological changes, and
cancer predisposition. In contrast to TP53 and RB mutations,
the RecQ mutations have not been commonly found in
somatic tissue from sporadic cancer cases [52, 53]. Silencing
of RecQ expression through methylation has been proposed
as a mechanism by which these genes may be involved in
sporadic cancer without detectable mutations [53].
4.2. Rothmund-Thomson Syndrome (RecQL4). Rothmund
first described a syndrome of poikiloderma, growth retar-
dation, and bilateral cataracts among an inbred family in
Bavaria in 1868. Thomson, in 1923, reported a group of
patients with poikiloderma, growth retardation, and skeletal
abnormalities but without cataracts. In 1957, Taylor identi-
fied the two cohorts as the same syndrome [54]. Patients with
Rothmund-Thomson Syndrome (RTS) usually present with
erythema, swelling, and blistering of the face and extremities
between the age of 3 and 6 months. Mutations of RecQ4 (also
known as RecQL4) were identified as the cause of some cases
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Table 4: Physical findings of RecQ syndromes.
Syndrome Cutaneous Craniofacial Musculoskeletal Solid organ Other
RTS II
Poikiloderma
Sparse Hair
Dystrophic Nails
Frontal bossing
Saddle nose
Short Stature
Radial Defects
Hypoplastic Patellae
Esophageal or
Pyloric atresia
Annular pancreas
Myelodysplasi
Cataracts
RAPADILINO No Poikiloderma
Slender Nose
Cleft Palate
Short Stature
Radial Defects
Hypoplastic Patellae
Joint Dislocations
Diarrhea Normal intelligence
Werner
Tight, atrophic skin
Premature Graying
Bird-like Face
Short Stature
Flat Feet
Osteoporosis
Hypogonadism
Cataracts
Diabetes
Mellitus
Atherosclerosis
Bloom
Sun Sensitive Rash
Telangiectasias
Beaked Nose
Narrow Face
Short Stature Lung disease
High Pitch Voice
Mental retardation
of RTS in 1999 [55]. Subsequent research has identified two
types of RTS. Type 1 RTS patients lack RecQ4 mutations,
develop cataracts, and are not predisposed to osteosarcomas.
The gene responsible for Type 1 RTS is unknown at this time.
Type 2 RTS patients have RecQ4 mutations, a greater number
and severity of skeletal abnormalities, and a predisposition to
osteosarcomas [56]. RecQ4 is unique among the RecQ family
in that it lacks detectable DNA helicase activity and possesses
single-stranded DNA annealing activity [57]. Researchers
hypothesize that RecQ4 functions in DNA repair.
A 2008 review of the world literature identified 61 cases of
cancer among all reported RTS patients, of which 38 (62%)
were osteosarcomas. Three cases were multicentric (meta-
chronous) osteosarcoma, and 12 cases developed before age
10, with the overall average age of presentation at 14 years
[58]. Another cohort of 41 RTS patients contained a 31%
incidence of osteosarcoma with a mean age of 11.5 years and
4 multicentric cases [54]. The same authors recommended
obtaining baseline long bone radiographs by age five in
RTS patients. They recommended this imaging in order to
identify subtle skeletal dysplasia findings as well as to provide
a baseline comparison if the patients developmusculoskeletal
symptoms concerning for osteosarcoma later in life. A 2003
study of 33 RTS patients found an association between gene
truncation (as opposed to nonsense or missense) mutations
and osteosarcoma development [59]. The authors proposed
that this genotype/phenotype correlation may be useful
in identifying RTS patients at increased risk of developing
osteosarcoma.
4.3. RAPADILINO Syndrome (RecQ4). A second syndrome
associated with osteosarcoma and caused by RecQ4 muta-
tions has only recently been described. The name is an
acronym of the major clinical findings (RA: RAdial aplasia
or hypoplasia, PA: PAtellae aplasia or hypoplasia and cleft
or high arched PAlate, DI: DIarrhea and DIslocated joints,
LI: LIttle size and LImb malformations, NO: long, slender
NOse and NOrmal intelligence). Notably, the hallmark poik-
iloderma of RTS is absent among RAPADILINO patients.
A 1989 report from Finland first identified the syndrome
in 5 patients [60]. The disease is extremely rare and pre-
dominantly found in Finland although cases in other parts
of the world have been reported. In 2003, RecQ4 muta-
tions were identified as the cause [61]. Osteosarcoma was not
initially thought to be associated with the condition; how-
ever, a 2009 study found that 2 of 15 (13.3%) known cases
in Finland developed osteosarcoma [62]. Based upon these
data, RAPADILINO should be included in the list of osteo-
sarcoma predisposition syndromes. Baller-Gerold syndrome,
the third condition associated with mutation of RecQ4, is
characterized by radial aplasia and craniosynostosis. It has
not been associated with osteosarcoma [62].
4.4. Werner Syndrome (WRN). Werner syndrome (WS), also
known as adult progeria, is a rare autosomal recessive condi-
tion characterized by premature aging, short stature, bilateral
cataracts, and distinctive skin changes [63]. The condition is
overrepresented in Japan, presumably due to a founder effect
similar to RAPADILINO syndrome. Diagnosis is often not
made until the fourth decade of life [64]. WS is caused by
mutations of the WRN gene which was first cloned in 1996
[65]. The WRN gene product is the only human RecQ family
member with 3′ to 5′ exonuclease activity. The relevance of
this finding to the unique progeria phenotype present in WS
has not been determined.
In a 1996 review of the world literature, osteosarcomas,
soft tissue sarcomas, myeloid disorders, benign menin-
giomas, thyroid cancers, and melanomas were overrepre-
sented in WS. Thirteen of 186 (7%) cancers among WS pa-
tients were osteosarcomas [66]. A subsequent study of Japa-
nese WS patients found that the presentation of osteosar-
coma in their cohort was atypical. The WS patients devel-
oped osteosarcomas at an older age, ranging from 35 to 57.
Seven of 10 cases presented in the foot and ankle while one
other case presented in the patella (rather than in the long
bones typical for osteosarcoma). Half of the osteosarcoma
patients also developed additional cancers including three
soft tissue sarcomas and three thyroid cancers [67]. Oste-
osarcomas are treated with standard therapies in WS, and
there is no consensus about avoidance of radiation. Because
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WS is often diagnosed later in life, development of late-
onset osteosarcoma may be a presenting complaint of the
syndrome.
4.5. Bloom Syndrome (BLM). Bloom syndrome (BS) was first
described in 1954. It is characterized by short stature, sun-
sensitive rash, and sparseness of subcutaneous fat through-
out infancy and early childhood. Mutations of the BLM gene
were identified as the cause in 1995 [68]. The same study
identified BLM as a RecQ homologue, the first homologue
to be identified in humans despite being rarer than RTS
and WRN. BS primarily affects Ashkenazi Jews due to a
founder effect, but cases have been identified in other ethnic
groups, as well [69]. In addition to cancer predisposition,
feeding difficulties during infancy and susceptibility to ear
and respiratory infections are common clinical problems.
A review of the first 100 cancers among patients followed
in Bloom registry was published in 1997. BS differed from
the other RecQ syndromes in that the majority (95%) of the
cancers were common carcinomas, leukemias, and lympho-
mas found in the general population [70]. However, the BS
registry also contained two osteosarcomas, two Wilm’s tu-
mors, and one medulloblastoma. Although the incidence of
osteosarcoma in BS is not as high as the previously described
syndromes, it far exceeds the expected rate in the general
population. Genetic testing for BLM mutations is clinically
available. The heterozygosity rate among Ashkenazi Jews in
New York City is approximately 1%, and testing for BLM
mutations is therefore encouraged in this population [71].
Osteosarcomas among BS patients are treated with standard
chemotherapy regimens. Screening includes routine physical
examinations and earlier initiation of colon cancer screening
protocols.
4.6. Diamond Blackfan Anemia (S19 and Other Ribosomal
Proteins). Diamond Blackfan Anemia (DBA) was first des-
cribed in 1938 and is characterized by severe pure red blood
cell aplasia diagnosed at less than one year of age, frequent
congenital abnormalities, and a predisposition to cancer. The
condition is clinically and genetically heterogeneous. The
North American registry had 420 patients as of 2006, and the
estimated incidence of DBA is between 1 in 100,000 and 1 in
200,000 live births [72]. Although rare, DBA is more com-
mon than the previously described RecQ syndromes. The
male-to-female ratio is equivalent, and DBA rates are similar
in different countries [73]. Most patients are diagnosed early
in infancy, but there are cases of adult diagnosis due to
incomplete penetrance of the condition [73]. Congenital
anomalies are found in 35–47% of DBA patients, and com-
monly include craniofacial (50% of all defects), thumb,
heart, and renal abnormalities [73]. Treatment of the anemia
may include corticosteroids, transfusions, and bone marrow
transplantation. Approximately 50% of DBA cases have a
known geneticmutation [74]. Ribosomal protein S19 was the
first causative gene to be cloned in 1999 [75]. Subsequently,
mutations of eight more ribosomal protein genes were iden-
tified as causes of DBA.
Of the approximately 700 DBA cases reported in the liter-
ature, 29 developed cancer [73]. Hematologic malignancies
were most common, but six cases of osteosarcoma have been
reported, more than would be expected in the general pop-
ulation [76]. Standard treatment protocols for osteosarcoma
are recommended in DBA; however, all three cases of osteo-
sarcoma reported in the North American DBA registry
had difficulty completing chemotherapy due to cytopenia
presumably related to their DBA. The limited number of pa-
tients with both conditions precludes analysis of whether
having underlying DBA affects survival. There are no formal
osteosarcoma surveillance protocols currently recommended
for DBA other than close vigilance for bone pain and skeletal
masses.
5. Summary and Future Direction
Osteosarcoma may be the presenting diagnosis in several
of the hereditary syndromes described above including LFS,
RTS, WS, and BS. Clinicians who treat osteosarcoma should
always consider the possibility of an associated predisposi-
tion syndrome, especially in cases of osteosarcoma with an
unusual presentation or in patients with a family history of
cancer or congenital malformations. A 2005 study from the
Netherlands identified definite or suspected malformation
syndromes in 7.2% of an unselected cohort of 1,073 pediatric
cancer patients [77]. Most notably, 20 of the 42 definite syn-
drome diagnoses were not identified prior to evaluation for
the study. The authors concluded that all children with mali-
gnancy may benefit from examination by a clinical geneticist
or pediatrician skilled in clinical morphology. Early identifi-
cation of patients with predisposition syndromes permits
treatment of associated pathologies, better cancer surveil-
lance, and genetic testing of at-risk family members. A recent
prospective study of 33 patients with germline TP53 muta-
tions compared intensive and standard surveillance for asso-
ciated cancers [78]. Intensive surveillance included annual
whole body MRI, annual brain MRI, and blood tests every
four months. Solid tumors among the intensive surveillance
group were identified at an early stage and were surgically
resectable. The intensive surveillance group had statistically
significant lower mortality at average 2 year followup.
The syndromes reviewed in this paper are rare and often
difficult to diagnose unless the clinician has a high index
of suspicion. Once identified, patients with these hereditary
conditions require frequent and intense medical followup
accompanied by referral to a cancer genetics clinic. Pro-
gress in the treatment of these conditions has been facilitated
by timely and accurate reporting of cases in the literature.
National and international registries exist for most of these
syndromes to facilitate their study and treatment, and clini-
cians should enroll their patients in these registries. Patients
with osteosarcoma predisposition syndromes are best served
by treatment at centers familiar with these rare syndromes.
Multidisciplinary care of these patients and their families
requires sophisticated genetic testing and counseling in addi-
tion to treatment of the disease. Although rare, the study
of these hereditary syndromes has provided fundamental in-
sights into cancer biology in general and the pathogenesis of
osteosarcoma in particular.
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